Synbiotic Se · XETR:SBX
Synbiotic — Investor Presentation (October 2025)
23 slides from Synbiotic's investor presentation, October 2025
Slide 1: Integrated Investment Platform for the Cannabis and Hemp Markets in Germany and Europe
Ticker: SBX.DE (Xetra) | WKN: A3E5A5 | ISIN: DE000A3E5A59 Integrated Investment Platform for the Cannabis and Hemp Markets in Germany and Europe Date: October 2025
Slide 2: Opportunity to capitalize on the growing cannabis and hemp markets
Offering the exceptional opportunity to fully capitalize on the rapidly growing cannabis and hemp markets European holding company publicly listed on the German stock market Integration into the entire value chain, both horizontally and vertically, from seed to shelf Creating a profitable synergy ac
Slide 3: Vision becomes Reality
Vision becomes Reality "The rediscovery of cannabis and hemp has become a reality. We are in the midst of the dawn of the next great cannabis and hemp era.” Daniel Kruse, CEO SYNBIOTIC SE, 2024 Our vision is to make the versatile applications of medical cannabis as well as industrial hemp, including
Slide 4: Numbers of SYNBIOTIC SE
Numbers of SYNBIOTIC SE 51 12 Employees (FTE) Ventures > 15.000 > 33.000 Shareholders Active Customers WKN: A3E5A5 | ISIN: DE000A3E5A59 4
Slide 5: Business Sectors & Strategic Focus
Business Sectors & Strategic Focus Medical cannabis Industrial hemp Strategic Focus 2025 - 2027 Import partnerships in the Cultivation Netherlands, Denmark, Spain, Portugal, Thailand and Canada 20% R&D / Production 20% 60% Sales & Medical cannabis Distribution CBD Industrial hemp WKN: A3E5A5 | ISIN:
Slide 6: Germany shapes the Future of Medical Cannabis in Europe
Germany shapes the Future of Medical Cannabis in Europe With strong momentum and regulatory transformation ahead, the German medical cannabis market is entering a new era of growth and is Europe’s #1 growth opportunity German medical cannabis market 800 762.85 750 732.24 Million EURO 704.90 700 678.
Slide 7: Europe's Medical Cannabis Market is opening up
Europe’s Medical Cannabis Market is opening up European cannabis market Opportunities The European medical cannabis market is on the doorstep of a boom, with double-digit growth rates and multi-billion-euro potential Europe is becoming the world’s largest import region for medical cannabis, with a s
Slide 8: Global Cannabis Market grows excessively
Global Cannabis Market grows excessively Global cannabis market is about to grow from $5.2B (2024) to $72.7B (2030) at a CAGR of 55.1% Healthcare systems around the world are evolving rapidly, boosted by emerging markets General growing acceptance of cannabis supports integration into mainstream med
Slide 9: Industrial Hemp – a global Billion-Dollar Market
Industrial Hemp – a global Billion-Dollar Market Global industrial hemp market Opportunities 20 Hemp is the ideal second revenue stream – capitalizing on similar 17 infrastructure while unlocking new high-growth markets Upcoming positive reassessment of the status of industrial hemp 15 Billion USD t
Slide 10: Hemp as major Source for Securing the Global Food Supply
Hemp as major Source for Securing the Global Food Supply Hemp is as a major source for plant-based meat alternatives A vegetable source of protein, essential fatty acids and fibre Supports a balanced and healthy diet for humans and animals Source: https://www.imarcgroup.com/hemp-based-food-market-st
Slide 11: SYNBIOTIC – Strategic Market Positioning & Innovation
SYNBIOTIC – Strategic Market Positioning & Innovation Strategic focus on high-growth segments – medical cannabis Strong focus on the fast-growing medical cannabis market segment. Targeting both prescription-based therapeutics and emerging OTC products. Diversified industrial hemp strategy Broad posi
Slide 12: Medical Cannabis Ventures - Competitive Edge & Innovation
Medical Cannabis Ventures - Competitive Edge & Innovation WEECO Pharma: trusted German cannabis wholesaler GDP licensed with broad access to leading EU-GMP cannabis manufacturers Strong European manufacturer network and specialization in international medical cannabis trade Proprietary genetics and
Slide 13: Medical Cannabis Ventures - Competitive Edge & Innovation
Medical Cannabis Ventures - Competitive Edge & Innovation SYNBIOTIC Distribution: sales channel for alternative dosage forms Well trusted supplier for the import and distribution of high-quality medical cannabis products in Germany since 2017 Potential specialised distribution channel for cannabinoi
Slide 14: Industrial Hemp Ventures - Competitive Edge & Innovation
Industrial Hemp Ventures - Competitive Edge & Innovation Hanf Farm: cultivation of hemp with quality “made in Germany” Hanf Farm is a well-established company recognised for its long-standing commitment to cultivation, processing, and distribution of premium hemp Hemp Factory: state-of-the-art produ
Slide 15: Industrial Hemp Ventures - Competitive Edge & Innovation
Industrial Hemp Ventures - Competitive Edge & Innovation SOLIDMIND Group: one of first and most known market leaders in CBD Highly trusted CBD brands Hempamed and BioCBD Experienced online sales and marketing team More than 300.000 customers over the last 8 years Lean Labs: ready-to-sell processing
Slide 16: Convincing Unique Selling Points
Convincing Unique Selling Points Operational Excellence Improved operating results through scalable structures, lean processes, and disciplined cost control MedCan as Primary Growth Engine Disproportionately strong growth forecast between 2025 - 2027 due to rising demand, regulatory shifts, and prod
Slide 17: Innovative Development Pipeline – Medical Cannabis
Innovative Development Pipeline – Medical Cannabis Pastille: New application form with accelerated onset of action Astrum: Self Emulsifying Drug Delivery System with CBD DronaSine: Novel concept for preservative-free oral administration of dronabinol Pastille Research Development Data & Legal Market
Slide 18: Forecast Revenue Drivers
Forecast Revenue Drivers Short-term (started 2024): Medical cannabis Established revenue foundation through distribution of high-quality medical cannabis products under existing regulatory framework and growing patient demand Short-term (starting 2025): Hemp-based food ingredients Strong increase in
Slide 19: Analyst Reports
Analyst Reports Click on reports to access WKN: A3E5A5 | ISIN: DE000A3E5A59 19
Slide 20: Share Opportunities & Cap Table
Share Opportunities & Cap Table High visibility and widespread shareholder engagement create a solid foundation for long-term capital support and trading activity Trust in financial statements (IFRS) that are externally audited Broad investor base with approx. 15,000 shareholders Strong potential fo
Slide 21: Experienced Leadership
Experienced Leadership SYNBIOTIC SE Management: More than 100 years of combined experience in the medical cannabis and industrial hemp sectors Leading positions in lobby groups (FIHO, EIHA, BvCW) Ideally positioned to take on a leading role in this dynamic and growing market, both operationally and
Slide 22: Contact
Ticker: SBX.DE (Xetra) | WKN: A3E5A5 | ISIN: DE000A3E5A59 Münsterstrasse 336 | 40470 Düsseldorf | Germany synbiotic.com | ir@synbiotic.com Managing Director: Daniel Kruse Chairman of the Board of Directors: Oliver Conrad 22
Slide 23: Disclaimer and Legal Notice
Disclaimer and Legal Notice This presentation is only for professional investors. This presentation contains certain forward-looking statements that reflect assumptions, opinions, expectations and views of the company or third parties. Various known and unknown risks, uncertainties and other factors